Company intelligence / Profile preview

Syntone Ventures

United States

Ownership: Private
Development stage: Other

Overview

Syntone Ventures, LLC is a venture investor and major shareholder in Outlook Therapeutics, a late clinical-stage biopharma company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retinal diseases including wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Industry: Investors

Partnerships

Outlook Therapeutics

Beyond the preview

Go deeper on Syntone Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntone Ventures.

Explore the full profile